Clinical image: hidden costs of anti-tumor necrosis factor alpha therapy.
Mulherin
D
D
Cannock Chase Hospital, Cannock, UK.
Sheeran
T P
TP
D000911:Antibodies, Monoclonal / Q000191:economics* / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000191:economics* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000191:economics*; D003362:Cost-Benefit Analysis; D004853:Epoxy Resins; D006801:Humans; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D010796:Phthalic Anhydrides; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000191:economics* / Q000627:therapeutic use; D014925:Wit and Humor as Topic
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D004853:Epoxy Resins; D010796:Phthalic Anhydrides; D014409:Tumor Necrosis Factor-alpha; C005752:araldite; D000069285:Infliximab